TetraCore Therapeutics is a commercial-stage biopharmaceutical company focused on therapeutics for eye care and infectious disease, built on the selective antiparasitic mechanism of lotilaner. The company's flagship product is an FDA-approved topical ophthalmic solution targeting Demodex blepharitis, a widespread eyelid condition caused by mite infestation that can progress to corneal damage and blindness if untreated. TetraCore generates revenue through direct specialty sales and direct-to-consumer marketing in the United States, maintains high insurance coverage rates, and pursues international licensing partnerships; its pipeline extends the same core mechanism to treat additional conditions including meibomian gland disease, ocular rosacea, and Lyme disease prophylaxis, while managing tiered royalty obligations under an exclusive license from a pharmaceutical partner.